Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Center, Single-Dose, Open-Label, Laboratory-Blind, Randomized, Two-Period Crossover Study to Determine the Bioequivalence of Two Nicotine Resinate Lozenge Formulations Containing Nicotine 2 mg in up to 42 Healthy Male and Female Smokers Under Fasting Conditions

NCT03432273 is registered in ClinicalTrials.gov with Fertin Pharma A/S as lead sponsor.

NCT NCT03432273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03432273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Center, Single-Dose, Open-Label, Laboratory-Blind, Randomized, Two-Period Crossover Study to Determine the Bioequivalence of Two Nicotine Resinate Lozenge Formulations Containing Nicotine 2 mg in up to 42 Healthy Male and Female Smokers Under Fasting Conditions
Lead sponsor
Fertin Pharma A/S
Phase
Phase 1
Overall status
Completed
Start date
February 19, 2018
Completion date
March 27, 2018
Enrollment
42 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

smoking cessation